Quarterly Development Reports. PII shall furnish to the alliance manager as may be designated from time to time by RBX (the “Alliance Manager”) a quarterly written report detailing the progress of the Development, including successes, difficulties, milestone achievements and a comparison of the status of the Development as compared to the Development timeline contained in the Development Plan, including (i) a description of the status of the preparation, filing and receipt of Regulatory Approvals relating for the Licensed Product(s) in the Territory, (ii) any updates or modifications to the Development Plan, and (iii) the estimated date of the First Commercial Sale of the Licensed Products in each country of the Territory in which PII has submitted agency applications for Regulatory Approval of the Licensed Product(s). Such reports shall constitute Confidential Information under Article IX and RBX will limit disclosure to its employees on a strict need-to-know basis. The first quarterly report shall be provided to RBX on April 1, 2007 and on the first day of each July, October, January and April thereafter. [*] Confidential treatment requested; certain information omitted and filed separately with the SEC.
Appears in 4 contracts
Samples: Option and License Agreement (Furiex Pharmaceuticals, Inc.), Option and License Agreement (Furiex Pharmaceuticals, Inc.), Option and License Agreement (Furiex Pharmaceuticals, Inc.)
